The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic.
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...